These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14556430)

  • 1. Pharmacological principles governing the use of proton pump inhibitors: tailoring therapy to improve GERD outcomes. Preface.
    Wolfe MM
    Gastroenterol Clin North Am; 2003 Sep; 32(3 Suppl):vii-ix. PubMed ID: 14556430
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety data required for proton-pump inhibitor use in children.
    Scaillon M; Cadranel S
    J Pediatr Gastroenterol Nutr; 2002 Aug; 35(2):113-8. PubMed ID: 12187284
    [No Abstract]   [Full Text] [Related]  

  • 3. Managing gastroesophageal reflux disease: from pharmacology to the clinical arena.
    Wolfe MM
    Gastroenterol Clin North Am; 2003 Sep; 32(3 Suppl):S37-46. PubMed ID: 14556434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
    Xue S; Katz PO; Banerjee P; Tutuian R; Castell DO
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nocturnal acid breakthrough in perspective: let's not throw out the baby with the bath water.
    Castell DO
    Am J Gastroenterol; 2003 Mar; 98(3):517-8. PubMed ID: 12650778
    [No Abstract]   [Full Text] [Related]  

  • 6. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.
    Thjodleifsson B
    Expert Opin Pharmacother; 2004 Jan; 5(1):137-49. PubMed ID: 14680443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laryngopharyngeal reflux disease with nocturnal gastric acid breakthrough while on proton pump inhibitor therapy.
    Sato K
    Eur Arch Otorhinolaryngol; 2006 Dec; 263(12):1121-6. PubMed ID: 16845517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
    Nzeako UC; Murray JA
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections.
    Waldum HL; Brenna E; Sandvik AK
    Expert Opin Drug Saf; 2002 May; 1(1):29-38. PubMed ID: 12904157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids.
    Theisen J; Nehra D; Citron D; Johansson J; Hagen JA; Crookes PF; DeMeester SR; Bremner CG; DeMeester TR; Peters JH
    J Gastrointest Surg; 2000; 4(1):50-4. PubMed ID: 10631362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid secretion from birth to adulthood.
    Boyle JT
    J Pediatr Gastroenterol Nutr; 2003; 37 Suppl 1():S12-6. PubMed ID: 14685072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of chronic therapy for GERD. Preface.
    Fass R
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S1. PubMed ID: 19262539
    [No Abstract]   [Full Text] [Related]  

  • 13. Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.
    Hatlebakk JG
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():10-5; discussion 16-7. PubMed ID: 12614300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of gastroesophageal reflux disease.
    Pettit M
    Pharm World Sci; 2005 Dec; 27(6):432-5. PubMed ID: 16341949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux.
    Sen P; Georgalas C; Bhattacharyya AK
    Clin Otolaryngol; 2006 Feb; 31(1):20-4; discussion 24. PubMed ID: 16441796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
    Neal K; Logan R
    Aliment Pharmacol Ther; 2001 Jul; 15(7):1085-6. PubMed ID: 11421886
    [No Abstract]   [Full Text] [Related]  

  • 17. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
    Egan LJ; Myhre GM; Mays DC; Dierkhising RA; Kammer PP; Murray JA
    Aliment Pharmacol Ther; 2003 Jun; 17(12):1521-8. PubMed ID: 12823155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
    Gardner JD; Sloan S; Miner PB; Robinson M
    Aliment Pharmacol Ther; 2003 Apr; 17(7):955-64. PubMed ID: 12656698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric acid suppressants--too much of a good thing?
    Logan IC; Sumukadas D; Witham MD
    Age Ageing; 2010 Jul; 39(4):410-1. PubMed ID: 20507846
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of gastroesophageal reflux disease.
    Stanghellini V
    Drugs Today (Barc); 2003 Mar; 39 Suppl A():15-20. PubMed ID: 12712217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.